文献速递中药与中成药合理使用中医内科

复方白鲜皮方靶向IL-17A抑制PI3K-AKT/JAK2-STAT3双通路改善银屑病

Integrating network pharmacology, transcriptomics, and experimental validation: Compound Baixianpi Formula targets IL-17A to inhibit dual PI3K-AKT/JAK2-STAT3 pathways for psoriasis improvement.
PubMed 文献 · Chin Med · 2026-05-22

研究采用网络药理学、转录组学与实验验证相结合的策略,探究复方白鲜皮方(FFBXP)治疗银屑病的物质基础与机制。在IMQ小鼠银屑病模型和TNF-α刺激的HaCaT细胞模型中,FFBXP改善皮损、降低炎症因子(IL-17A、IL-23、TNF-α)与氧化应激标志物(MDA),并抑制PI3K-AKT与JAK2-STAT3通路磷酸化。

要点

  • FFBXP可改善银屑病样小鼠红斑与皮损浸润,降低IL-17A、IL-23、TNF-α及MDA水平。
  • FFBXP剂量依赖性抑制TNF-α诱导的HaCaT细胞增殖,减轻氧化应激并促进凋亡。
  • FFBXP靶向IL-17A并协同抑制PI3K-AKT与JAK2-STAT3双通路。

核心结论

  • FFBXP通过靶向IL-17A并协同抑制PI3K-AKT和JAK2-STAT3两条关键信号通路发挥抗银屑病作用。

研究设计与样本

  • 采用UHPLC-Q-Orbitrap HRMS鉴定FFBXP成分,整合网络药理学与转录组学筛选核心靶点与通路。
  • 使用IMQ小鼠银屑病模型和TNF-α刺激的HaCaT细胞模型评估FFBXP对皮损、组织病理、氧化应激及炎症介质的影响。
  • 通过分子对接、qRT-PCR、Western blot和免疫荧光验证关键机制。

主要发现

  • 体内实验显示FFBXP显著改善银屑病小鼠红斑和皮损浸润,降低IL-17A、IL-23、TNF-α及MDA水平。
  • 体外实验证实FFBXP剂量依赖性抑制TNF-α诱导的HaCaT细胞增殖,降低炎症因子水平,减轻氧化应激并促进凋亡。
  • 网络药理学与转录组学分析提示机制涉及IL-17、PI3K-AKT和JAK2-STAT3信号通路。
  • 分子对接显示6种核心活性成分(小檗碱、白藜芦醇、槲皮素、儿茶素、山柰酚、蛇床子素)与关键靶蛋白具有良好结合活性。

临床怎么用

  • FFBXP作为临床有效的局部中药复方,其抗银屑病作用与靶向IL-17A及抑制PI3K-AKT/JAK2-STAT3通路相关。
  • 核心活性成分小檗碱、白藜芦醇、槲皮素、儿茶素、山柰酚和蛇床子素与关键靶蛋白结合良好,可为质量标志物研究提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is an immune-mediated chronic inflammatory skin disease. Existing therapies have limitations, necessitating the development of new treatment approaches. Compound Baixianpi Formula (FFBXP) is a clinically effective topical Chinese herbal formula, but its material basis and mechanism of action remain unclear. MATERIALS AND METHODS: FFBXP components were identified using UHPLC-Q-Orbitrap HRMS. Core targets and pathways were screened by integrating network pharmacology and transcriptomics analyses. The effects of FFBXP on skin lesions, histopathology, oxidative stress, and inflammatory mediators (IL-17A, IL-23, TNF-α) were evaluated using a IMQ mouse psoriasis model and a TNF-α-stimulated HaCaT cell model. Key mechanisms were validated through molecular docking, qRT-PCR, Western blot, and immunofluorescence techniques. RESULTS: Forty-two active components were identified in FFBXP. In vivo experiments demonstrated that FFBXP significantly improved erythema and skin lesion infiltration in psoriatic mice, while reducing levels of inflammatory cytokines (IL-17A, IL-23, TNF-α) and oxidative stress markers (MDA). In vitro experiments confirmed that FFBXP dose-dependently inhibited TNF-α-induced proliferation in HaCaT cells, reduced inflammatory cytokine levels, mitigated oxidative stress, and promoted apoptosis. Network pharmacology and transcriptomics analysis indicated its mechanism involves IL-17, PI3K-AKT, and JAK2-STAT3 signaling pathways. Molecular docking showed that six core active ingredients (berberine, resveratrol, quercetin, catechin, kaempferol, and osthol) had good binding activity with key target proteins. Further mechanism validation revealed FFBXP significantly decrease IL-17A expression and inhibited phosphorylation of downstream PI3K, AKT, JAK2, and STAT3 proteins. CONCLUSION: This study employs a combined strategy of network pharmacology, transcriptomics, and experimental validation to elucidate for the first time that FFBXP exerts its anti-psoriasis effects by targeting IL-17A and collaboratively inhibiting two key signaling pathways: PI3K-AKT and JAK2-STAT3.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Tang L, Wang Y, Zhou Y, et al. Integrating network pharmacology, transcriptomics, and experimental validation: Compound Baixianpi Formula targets IL-17A to inhibit dual PI3K-AKT/JAK2-STAT3 pathways for psoriasis improvement. Chin Med. 2026. PMID: 42174671. doi:10.1186/s13020-026-01386-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。